Clinical characteristics and immunogenetics of BCGosis/BCGitis in Chinese children: a 6 year follow-up study.
In this study, the clinical and immunogenetical features in a cohort of Chinese patients with BCGosis/BCGitis were investigated. For the patients with abnormal immunological functions, Sanger sequencing was used to identify the involved genes. There were 74 confirmed cases of BCGosis/BCGitis during 2007-2012. Classified by infected tissues and organs, no cases only had local infection, 39 patients had a regional infection, 21 patients had a distant infection and 14 patients had a disseminated infection. Thirty-two patients (43.2%) had definitive primary immunodeficiency diseases (PID) and chronic granulomatous disease (CGD) is the most common PID (n = 23, accounted for 71.9% of all PID patients). For CGD patients, based on the anti-tuberculosis treatment, administration of rhIFN-γ resulted in better control of BCGosis/BCGitis. The results indicate that PIDs are associated with susceptibility to BCG disease. For children with BCGosis/BCGitis, immune function evaluation is necessary, and IFN-γ treatment for BCGosis/BCGitis patients with CGD is effective.
Department of Clinical Immunology, Children's Hospital of Fudan University, Shanghai, China.
Wenjing
W
Ying
Department of Clinical Immunology, Children's Hospital of Fudan University, Shanghai, China.
Jinqiao
J
Sun
Department of Clinical Immunology, Children's Hospital of Fudan University, Shanghai, China.
Danru
D
Liu
Department of Clinical Immunology, Children's Hospital of Fudan University, Shanghai, China.
Xiaoying
X
Hui
Department of Clinical Immunology, Children's Hospital of Fudan University, Shanghai, China.
Yeheng
Y
Yu
Department of Clinical Immunology, Children's Hospital of Fudan University, Shanghai, China.
Jingyi
J
Wang
Department of Clinical Immunology, Children's Hospital of Fudan University, Shanghai, China.
Xiaochuan
X
Wang
D001500:BCG Vaccine / Q000008:administration & dosage / Q000009:adverse effects*; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007125:Immunogenetics; D007136:Immunoglobulins / Q000097:blood; D007153:Immunologic Deficiency Syndromes / Q000276:immunology* / Q000503:physiopathology; D007223:Infant; D007231:Infant, Newborn; D007371:Interferon-gamma / Q000627:therapeutic use; D016131:Lymphocyte Subsets / Q000276:immunology; D008297:Male; D009165:Mycobacterium Infections, Nontuberculous / Q000188:drug therapy / Q000209:etiology / Q000276:immunology* / Q000503:physiopathology; D012720:Severity of Illness Index; D014376:Tuberculosis / Q000517:prevention & control
D001500:BCG Vaccine; D007136:Immunoglobulins; D007371:Interferon-gamma